NCT04735003

Brief Summary

This is an observational, multi-center, retrospective and prospective study collecting data about patients undergoing transcatheter tricuspid valve interventions in a real world clinical environment. The aim is to report clinical characteristics, procedural results and short- and long-term outcomes of patients undergoing transcatheter tricuspid valve interventions in Italian centres.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
9mo left

Started Jan 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress88%
Jan 2021Jan 2027

First Submitted

Initial submission to the registry

January 16, 2021

Completed
14 days until next milestone

Study Start

First participant enrolled

January 30, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 2, 2021

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2026

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2027

Expected
Last Updated

February 2, 2021

Status Verified

January 1, 2021

Enrollment Period

5 years

First QC Date

January 16, 2021

Last Update Submit

January 30, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • All-cause death

    1-year

  • Cardiovascular death or heart failure hospitalization

    1-year

Secondary Outcomes (9)

  • Changes in tricuspid regurgitation degree

    30-day, 1-year and 5-year

  • Changes in NYHA class

    30-day, 1-year and 5-year

  • Changes in right ventricular dimensions and function

    30-day, 1-year and 5-year

  • Changes in liver and kidney function

    30-day, 1-year and 5-year

  • Changes in medical therapy (i.e. diuretic dose)

    30-day, 1-year and 5-year

  • +4 more secondary outcomes

Interventions

Transcatheter repair or replacement to treat tricuspid regurgitation

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with significant tricuspid regurgitation who need transcatheter tricuspid valve intervention.

You may qualify if:

  • Patients undergoing transcatheter treatment of tricuspid regurgitation (native valve -with or without previous surgical valve repair - or degenerated bioprosthesis)
  • Patients who are willing and capable of providing informed consent, and participating in all follow-ups associated with this clinical investigation.

You may not qualify if:

  • Valve anatomy unsuitable for transcatheter tricuspid valve interventions.
  • Subjects who are unable or not willing to complete follow-up visits and examination for the duration of the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Marianna Adamo

Brescia, Lombardy, 25123, Italy

RECRUITING

MeSH Terms

Conditions

Tricuspid Valve Insufficiency

Condition Hierarchy (Ancestors)

Heart Valve DiseasesHeart DiseasesCardiovascular Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

January 16, 2021

First Posted

February 2, 2021

Study Start

January 30, 2021

Primary Completion

January 30, 2026

Study Completion (Estimated)

January 30, 2027

Last Updated

February 2, 2021

Record last verified: 2021-01

Data Sharing

IPD Sharing
Will not share

Locations